LogicBio Therapeutics (LOGC) to Post Quarterly Earnings on Thursday

LogicBio Therapeutics (OTCMKTS:LOGC) will likely be releasing its Q2 2026 resultson Thursday, August 6th. Analysts expect the company to announce earnings of ($0.0414) per share and revenue of $22.4760 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

LogicBio Therapeutics Trading Down 0.5%

Shares of LOGC opened at $9.40 on Thursday. LogicBio Therapeutics has a fifty-two week low of $7.05 and a fifty-two week high of $10.35. The business has a 50-day moving average of $9.13 and a 200 day moving average of $8.51. The firm has a market cap of $429.91 million, a P/E ratio of -8.62 and a beta of 2.01. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.15 and a current ratio of 1.67.

Hedge Funds Weigh In On LogicBio Therapeutics

A hedge fund recently raised its position in LogicBio Therapeutics stock. Goldman Sachs Group Inc. raised its holdings in LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) by 284.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 526,673 shares of the company’s stock after purchasing an additional 389,843 shares during the period. Goldman Sachs Group Inc. owned 2.00% of LogicBio Therapeutics worth $3,676,000 at the end of the most recent reporting period. 46.05% of the stock is owned by hedge funds and other institutional investors.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics, Inc, a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.